title: Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11).
abstract: Neutral endopeptidase 24.11 (NEP), widely distributed in the body, hydrolyzes and inactivates a number of endogenous vasoactive peptides, some of which could alter various functions of cells present in the arterial wall. Recently NEP has been found to exist in the vascular endothelium. The aim of this study was to assess the influence of chronic NEP inhibition by daily administration of UK79300 (candoxatril), an orally active NEP inhibitor (NEPI), on the development of atherosclerotic changes in high-cholesterol-fed rabbits. Male New Zealand White rabbits were fed for 8 weeks as follows: normal rabbit diet (Normal, n = 15), 1.5% cholesterol diet (Cholesterol, n = 15), or 1.5% cholesterol diet containing NEPI (20 mg.kg-1.d-1) (Cholesterol+NEPI, n = 15). At the end of the dietary period, NEPI treatment was found to suppress the surface area of the aorta covered by plaques (% surface area: Cholesterol, 59 +/- 6 versus Cholesterol+NEPI, 36 +/- 7, P < .01) and decreased contents of cholesterol and cholesterol esters in the aortas. NEPI also reduced plasma total cholesterol by 27% of Cholesterol rabbits (1781 +/- 130 mg/dL). The endothelial function, estimated by the endothelium-dependent relaxation of the isolated aortas in response to acetylcholine, was preserved in Cholesterol+NEPI rabbits compared with that in Cholesterol rabbits. NEP enzymatic activities in plasma and the particulate fraction of the homogenates from the aortas in Cholesterol rabbits were both increased, 3.1- and 3.9-fold, respectively, above those in Normal rabbits, but the activities in Cholesterol+NEPI rabbits were significantly lower than those in Cholesterol rabbits. UK73967, an active form of UK79300, or phosphoramidon partly reversed the atherosclerotic impairment of relaxation of the isolated thoracic aortic rings from Cholesterol rabbits in response to exogenous additions of C-type natriuretic peptide (CNP) and substance P, which are NEP substrates known to exist endogenously in the vascular endothelium. The results suggest that the increased NEP activity plays a significant role in atherogenesis, and NEPIs might be therapeutically useful in the prevention of atherosclerosis. Reduction of plasma cholesterol and suppression of degradations in the arteries of endogenously released CNP, substance P, or possibly other kinins known to have anti-atherosclerotic actions may at least partially contribute to the inhibitory effects of NEPIs on atherosclerotic changes.
authors.affiliation: Division of Cardiology, Kumamoto University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kugiyama
authors.forename: S
authors.initials: S
authors.lastname: Sugiyama
authors.forename: T
authors.initials: T
authors.lastname: Matsumura
authors.forename: Y
authors.initials: Y
authors.lastname: Ohta
authors.forename: H
authors.initials: H
authors.lastname: Doi
authors.forename: H
authors.initials: H
authors.lastname: Yasue
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001013:Aorta, Thoracic; D001161:Arteriosclerosis / Q000517:prevention & control*; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002791:Cholesterol, Dietary / Q000008:administration & dosage / Q000494:pharmacology; D004036:Diet, Atherogenic; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006020:Glycopeptides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006937:Hypercholesterolemia / Q000150:complications*; D007189:Indans / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000032:analysis; D008297:Male; D020098:Natriuretic Peptide, C-Type; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000502:physiology; D009599:Nitroprusside / Q000494:pharmacology; D009924:Organ Culture Techniques; D011422:Propionates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011506:Proteins / Q000494:pharmacology; D011817:Rabbits; D013373:Substance P / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects
chemical_list: D002791:Cholesterol, Dietary; D004791:Enzyme Inhibitors; D006020:Glycopeptides; D007189:Indans; D008055:Lipids; D011422:Propionates; D011506:Proteins; D020098:Natriuretic Peptide, C-Type; D009599:Nitroprusside; D013373:Substance P; D009320:Atrial Natriuretic Factor; C062766:candoxatril; D015260:Neprilysin; C008890:phosphoramidon